🇺🇸 FDA
Pipeline program

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.

SWKCART24031101

Unknown small_molecule active

Quick answer

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. for Autoimmune Diseases is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Autoimmune Diseases
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials